ABSTRACT
The invention disclosed herein is directed to compounds of Formula I and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, acute or chronic myeloid leukemia, melanoma, and other cancers. The invention also includes pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, acute or chronic myeloid leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, acute or chronic myeloid leukemia, melanoma and other cancers through the administration of a therapeutically effective amount of a selective PPARa antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections.
To view the rest of the Patent Application click HERE.
Patent Application Number: 15/829514
Filing Date: 01 December 2017
Publication Date: 22 March 2018
Inventor information: Nicholas Simon Stock (Encinitas, CA, US); Austin Chih-yu Chen (San Marcos, CA, US); Yalda Mostofi Bravo (San Diego, CA, US); Jason Duarte Jacintho (San Diego, CA, US); & Yen Truong (San Diego, CA, US)
